Mereo BioPharma Group plc Sponsored ADR MREO 深 滬
等待開盤 05-20 09:30:00 美东时间
0.238
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 0.238
- 總市值 3798.92万
- 52周最高 3.05
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.20
- 委 比 0.00%
- 總股本 1.60亿
- 歷史最高 17.62
- 量 比 0
- 振 幅 0.00%
- 歷史最低 0.20
- 每 手 1
- 風險率 0.86%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Mereo BioPharma Shareholders Approve All AGM Resolutions
Mereo Biopharma Group Plc ( ($MREO) ) has shared an update. On May 14, 2026, Me...
05-14 22:49
Mereo BioPharma Group Q1 EPS $(0.01), Inline
Mereo BioPharma Group (NASDAQ:MREO) reported quarterly losses of $(0.01) per share which met the analyst consensus estimate. This is a 50 percent increase over losses of $(0.02) per share from the same period last year.
05-12 19:35
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Agilon Health (NYSE:AGL) stock increased by 22.1% to $34.0 during Wedn...
05-07 05:03
Mereo BioPharma Group Q4 EPS $(0.01), Inline
Mereo BioPharma Group (NASDAQ:MREO) reported quarterly losses of $(0.01) per share which met the analyst consensus estimate. This is unchanged from the same period last year.
03-19 21:37
Mereo BioPharma Reports Full Year 2025 Financial Results and Provides Corporate Highlights
Mereo BioPharma reported its financial results for 2025, focusing on advancements in setrusumab, alvelestat, and vantictumab. Setrusumab showed significant bone mineral density improvements in Phase 3 studies, though missed primary endpoints. Alvelestat's Phase 3 preparation is progressing, and vantictumab is set to begin a Phase 2 trial. The company ended 2025 with $41 million in cash, providing runway into mid-2027. Key programs are advancing, ...
03-19 12:30
Berger Montague files securities fraud class action against Mereo BioPharma Group plc
Berger Montague files securities fraud class action against Mereo BioPharma Group plc A securities fraud class action lawsuit has been filed against Mereo BioPharma Group plc on behalf of investors who bought the company’s American Depositary Shares between June 5, 2023 and December 26, 2025. The co
03-02 22:37
Rosen Law Firm Urges Mereo BioPharma ADS Investors to Join Securities Class Action by April 6, 2026
Rosen Law Firm Urges Mereo BioPharma ADS Investors to Join Securities Class Action by April 6, 2026 A securities class action has been filed involving Mereo BioPharma Group plc over alleged misstatements and omissions tied to expectations for the Phase 3 ORBIT and COSMIC studies of setrusumab in ost
02-20 06:48
Mereo BioPharma Receives Nasdaq Minimum Bid Price Notice
The latest announcement is out from Mereo Biopharma Group Plc ( ($MREO) ). On F...
02-18 07:11
2025全球十大失败临床试验
（来源：抗体圈） FierceBiotech每年梳理年度临床实验失败案例。2025年的这份榜单依旧偏向行业头部药企，也反映出一个现实，绝大多数高风险的中晚期...
02-13 12:22
美股大行评级 | 潜在上涨空间31.6%！巴克莱上调台积电目标价至450美元；第一地平线全国银行获5家机构上调目标价
今日重点评级关注：Guggenheim：维持MBX Biosciences"买入"评级，目标价从77美元升至88美元；摩根士丹利：维持DraftKings"超配"评级，目标价从50美元升至53美元
01-20 10:26
